Regeneron Reports Third Quarter 2026 Financial and Operating Results
Regeneron posted Q3 2026 revenue of $5.116 billion, up 36% year-over-year, with GAAP EPS of $18.45 (+35%) and non-GAAP EPS of $20.07 (+70%). Dupixent global net sales rose 35% to $6.54 billion and EYLEA HD U.S. sales jumped 62% to $699 million, while legacy EYLEA U.S. sales fell 41% on competition and patient transition to EYLEA HD.
Key figures
- Eps
- 18.45
- Revenue
- 5116000000
- Guidance
- FY2026: GAAP R&D $6.600-$6.735B (raised); non-GAAP R&D $6.050-$6.150B (raised); GAAP SG&A $2.730-$2.860B (lowered); non-GAAP SG&A $2.400-$2.500B (lowered); GAAP gross margin ~80% (raised from 78-79%); non-GAAP gross margin ~86% (raised from 84-85%)
- Revenue Yoy
- 36%
- Libtayo growth
- 51%
- Dupixent growth
- 35%
- Eylea us change
- -41%
- Gaap eps diluted
- 18.45
- Buyback remaining
- 2200000000
- Dividend per share
- 0.94
- Eylea hd us growth
- 62%
- Eylea us net sales
- 400000000
- Nongaap net income
- 2150000000
- Nongaap eps diluted
- 20.07
- Buybacks nine months
- 2300000000
- Eylea hd us net sales
- 699000000
- Sanofi upfront payment
- 1000000000
- Libtayo global net sales
- 550000000
- Free cash flow nine months
- 2904300000
- Sanofi collaboration revenue
- 2724000000
- Sanofi future milestones potential
- 7000000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.